Why the study?
JWHLGJD was developed to treat and prevent colorectal adenomas in China, but its active compounds and mechanisms remained to be discovered.
Design
Network pharmacology and molecular docking study
Authors
Loading...
Identifies candidate targets for JWHLGJD in CRA; hypothesis-generating and requires human validation before clinical consideration.
Network pharmacology and molecular docking identified key active compounds (berberine, stigmasterol) and targets (TP53, MAPK1) for JWHLGJD in treating colorectal adenomas.
Ji et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: